内皮祖细胞(endothelialprogenitorcells,EPCs)是造血干细胞一支骨髓衍生群。目前EPCs的鉴定是结合多方面的综合鉴定。在慢性阻塞性肺疾病(chronicobstructivepulmonarydisease,COPD)中,低氧刺激、正常迁移的趋化因子增加、外周循环过度消耗、反应性凋亡、营养缺乏,以及炎症因子刺激等综合因素导致EPCs数量改变,最终使组织修复能力和血管再生能力耗竭。干/祖细胞治疗在c()PD中拥有一定的运用前景,其移植过程中的安全性评估意义重大。
Endothelial progenitor cells(EPCs) are bone marrow-derived hematopoietic stem cells. Now the identification of EPCs is multi-disciplinary identification. In chronic obstructive pulmonary disease(COPD), hypoxia stimulation, chenmokine increasing, over-consumption, reactive apoptosis, nutritional deficiencies, and inflammatory cytokines lead to the changes in the number of EPCs, finally tissue repair capacity and blood vessel regeneration exhaust. Stem/progenitor cell therapy in COPD has a bright prospect. The safety assessment in transplantation is significant.